Med-IQ
<em>Decision-IQ:</em> Genetic Risk Assessment and Testing for Hereditary Ovarian Cancer
Decision-IQ Decision-IQ

Decision-IQ: Genetic Risk Assessment and Testing for Hereditary Ovarian Cancer


This activity was developed by Med-IQ in collaboration with Duke University Health System Department of Clinical Education and Professional Development.

Med-IQ      Duke Medicine
 

Time to Complete:
15 minutes
Released:
1/31/18
Expires:
1/30/19

Maximum Credits:

0.25 AMA PRA Category 1 Credit(s)
By clicking "Start," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Decision-IQ Decision-IQ
By clicking "Start," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.
Time to Complete:
15 minutes

Released:
1/31/18

Expires:
1/30/19

Maximum Credits:
0.25 AMA PRA Category 1 Credit(s)
Share on:
Decision-IQ Decision-IQ
By clicking "Start," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Share on:


Time to Complete:
15 minutes
Released:
1/31/18
Expires:
1/30/19


Maximum Credits:
0.25 AMA PRA Category 1 Credit(s)


Overview: In this brief case-based activity, meet Karen, a fictional 30-year-old woman whose mother recently died of ovarian cancer. Karen is now asking whether she should undergo genetic testing or ovarian cancer screening. As you move through this activity, read through links to useful resources to help you make clinical management decisions for Karen. You will also receive insights from expert faculty Andrew Berchuck, MD, on the latest recommendations for genetic testing and risk-reducing strategies for hereditary ovarian cancer.

Faculty

Andrew Berchuck, MD

James M. Ingram Professor of Gynecologic Oncology

Duke University School of Medicine

Durham, NC


Disclosure Policy

Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.


Disclosure Statement

The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.  

Andrew Berchuck, MD
Consulting fees/advisory boards: Merck & Co., Inc.

The peer reviewers and activity planners have no financial relationships to disclose.

This activity has been approved for AMA PRA Category 1 Credit™.


Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.